This article was originally published on 5 August 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. The JCVI subsequently reversed its Bexsero decision in March 2014.
Top-line performance
The top five vaccine companies reported approximately $4.70 billion in Q2 2013 and $9.08 billion for H1 2013 - a slight increase on the $8.9 billion recorded for the same H1 period in 2012. GSK Biologicals again led in dollar terms with $1.2 billion in Q2. Notable within the GSK results was Cervarix's 52% sales decline in H1 following Japan's HPV vaccine suspension, offset by mixed Infanrix/Pediarix franchise performance.
Combined H1 2013 vaccine revenues for the top five vaccine players, a slight increase over H1 2012
The Bexsero setback
The quarter's defining event was the UK JCVI's June 2013 decision not to recommend Novartis' meningococcal B vaccine Bexsero® for inclusion in the UK national immunisation programme - citing that the vaccine was unlikely to be cost-effective "at any vaccine price." The UK, with one of the highest MenB incidence rates in Europe, had been expected to be an early adopter. The JCVI decision cast a shadow over potential EU adoption in other member states, given the UK's traditional pioneering role in meningococcal vaccination.
QIV launches and Sanofi C.diff progression
On a more positive note, both GSK and Sanofi had received US FDA approval for quadrivalent influenza vaccines (QIV) and were preparing for their first commercial season. Sanofi shipped initial lots of QIV in July 2013. Sanofi also for the first time registered its Clostridium difficile vaccine programme (ACAM-CDIFF) in Phase 3 following FDA Fast Track designation.
Merck & Co recorded $1.2 billion Q2 with Gardasil growing 20% year-on-year - benefiting from a male indication in the US and the upcoming Brazil national HPV programme. Pfizer's Prevnar franchise at $969 million showed slight sequential improvement.
"Novartis' Bexsero setback does not bode well for the adoption of the vaccine in other EU member states - until the carriage data question is resolved."